Patents by Inventor Qingyu Wu
Qingyu Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230278445Abstract: The disclosure relates to the field of battery charging and swapping technologies, and specifically, to a wheel positioning method and system, a medium, an apparatus, and a battery charging and swapping station. The disclosure aims to resolve the problem of poor applicability of an existing four-wheel positioning method for a battery charging and swapping station.Type: ApplicationFiled: February 24, 2023Publication date: September 7, 2023Inventors: Jianglong LUO, Feifei ZHENG, Qingyu WU, Shuai WANG
-
Patent number: 11177019Abstract: The present invention relates to a method, device and software product for converting data into a data DNA sequence and restoring the DNA sequence library into raw data, and a storage medium for storing the software product. The method for converting data into a data DNA sequence comprises: dividing data into one or more data conversion units, providing a binary sequence for each data conversion unit, and converting each data conversion unit into a data DNA sequence according to a dataDNA sequence conversion rule, thus acquiring a data DNA sequence library, which makes biological storage of data in vivo possible by constructing a data DNA library.Type: GrantFiled: August 30, 2016Date of Patent: November 16, 2021Assignee: Tsinghua UniversityInventors: Junbiao Dai, Qingyu Wu, Naigemaiti Yijiati, Kaiwen Sun, Junkai Dong, Yiran Qin
-
Publication number: 20190311782Abstract: The present invention relates to a method, device and software product for converting data into a data DNA sequence and restoring the DNA sequence library into raw data, and a storage medium for storing the software product. The method for converting data into a data DNA sequence comprises: dividing data into one or more data conversion units, providing a binary sequence for each data conversion unit, and converting each data conversion unit into a data DNA sequence according to a dataDNA sequence conversion rule, thus acquiring a data DNA sequence library, which makes biological storage of data in vivo possible by constructing a data DNA library.Type: ApplicationFiled: August 30, 2016Publication date: October 10, 2019Inventors: Junbiao Dai, Qingyu Wu, Naigemaiti Yijiati, Kaiwen Sun, Junkai Dong, Yiran Qin
-
Patent number: 10314894Abstract: A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator.Type: GrantFiled: February 12, 2015Date of Patent: June 11, 2019Assignee: THE CLEVELAND CLINIC FOUNDATIONInventors: Qingyu Wu, Shenghan Chen
-
Publication number: 20160058848Abstract: A method of treating a cardio-renal disease is described that includes administering to a subject in need thereof a therapeutically effective amount of proprotein convertase subtilisin/kexin-6 (PCSK6), or an effective fragment thereof, which functions as a corin activator.Type: ApplicationFiled: February 12, 2015Publication date: March 3, 2016Inventors: Qingyu Wu, Shenghan Chen
-
Publication number: 20110306069Abstract: The invention is a method of assessing whether an individual is afflicted with congestive heart failure (CHF) comprising comparing the level of corin or portion thereof in the individual to the level of corin or portion thereof in a control, wherein a decrease in the level of corin or portion thereof in the individual compared to the level of corin or portion thereof in the control indicates that the individual is afflicted with CHF. The methods described herein can be also be used to determine the severity of CHF in an individual, whether an individual's treatment for CHF is effective and whether an individual is at risk of developing CHF.Type: ApplicationFiled: February 19, 2010Publication date: December 15, 2011Inventors: Qingyu Wu, Shenghan Chen, Edward Plow, Ningzheng Dong, Changgeng Ruan
-
Publication number: 20110160128Abstract: Provided herein are methods of inhibiting agouti or agouti-related protein (AGRP) in a cell or in an individual in need thereof, comprising administering to the cell or the individual an effective amount of an agent that induces corin expression, activity or a combination thereof in the cell or individual. The invention also provides a method of treating obesity in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual. Further provided is a method of treating diabetes type II in an individual in need thereof comprising administering to the individual an effective amount of an agent that enhances corin expression, activity or a combination thereof in the individual.Type: ApplicationFiled: March 25, 2009Publication date: June 30, 2011Inventors: Qingyu Wu, Jingjing Jiang, Wei Wang
-
Publication number: 20110086348Abstract: A method for assessing heart disease in a subject includes generating an expression profile of at least two or more miRNAs in a sample from the subject. The miRNAs can be selected from the group consisting of hsa-miRNA-1, hsa-miRNA-7, hsa-miRNA-29b, has-miRNA-125b, hsa-miRNA145, hsa-miRNA-181b, hsa-miRNA-214, hsa-miRNA-342, hsa-miRNA-378 and combinations thereof.Type: ApplicationFiled: February 19, 2010Publication date: April 14, 2011Inventors: Sathyamangla V. Naga Prasad, Sadashiva Karnik, Carlo Croce, Dianne M. Perez, Edward Plow, Christine Moravec, Subha Sen, Qingyu Wu, Randall C. Starling
-
Publication number: 20090298159Abstract: A method is provided to produce biodiesel from algae using a two-stage, autotrophic and heterotrophic cultivations of chlorella for biodiesel production. This method includes a sequence of procedures: cultivating photoautotrophic algae, concentrating cells and then transferring them to a fermentor for heterotrophic cultivation. During the photoautotrophic cultivation stage, the culture is exposed to a light source, such as sunlight with carbon dioxide obtained from a carbon dioxide source or from air. antibacterial agents may be added to prevent contamination from undesired microorganisms. Organic carbons are added during heterotrophic cultivation stage. Fermentation conditions are optimized for maximizing lipid synthesis. High biomass is achieved to about 108 g/L with lipid content reaching about 52% of dry cell weight. After cultivation, biodiesel is made through extraction and transesterification of algae lipids.Type: ApplicationFiled: November 20, 2008Publication date: December 3, 2009Inventors: Qingyu Wu, Wei Xiong
-
Publication number: 20090286721Abstract: This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of using these fusion proteins as thrombolytic agents, and processes for synthesizing these fusion proteins are also described herein.Type: ApplicationFiled: September 6, 2005Publication date: November 19, 2009Inventors: Junliang Pan, Qingyu Wu, Achim Schuttler, Annemarie Schuttler
-
Publication number: 20090211150Abstract: A method is provided to produce biodiesel from algae using a strain of microalga chlorella protothecoids, by screening a specific strain with characteristics of high yield of biomass and high oil content, cultivating the screened strain for high-cell-density growth for up to 108 grams of dry cell weight per liter of the suspension in a bioreactor using solutions containing carbohydrates as feed, harvesting and drying the high density cultivated algal cells to extract oil from the dried algal cells, and producing the biodiesel by reaction of catalyzed transesterification using the extracted oil as feedstock.Type: ApplicationFiled: April 4, 2008Publication date: August 27, 2009Inventors: Qingyu Wu, Wenguang Zhou, Wei Xiong
-
Patent number: 7176013Abstract: This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.Type: GrantFiled: June 9, 2004Date of Patent: February 13, 2007Assignee: Schering AktiengesellschaftInventor: Qingyu Wu
-
Publication number: 20050026255Abstract: The present invention relates to a corin polypeptide which contains one or more frizzled corin and possesses various activities, including, e.g., serin protease activity and a pro-ANF converting activity, LDLR, SRCR repeats, serine protease catalytic domains such as human and mouse corin. The invention further relates to methods of using such nucleic acids and polypeptides in therapeutics, diagnostics, and research. For example, the nucleic acids and polypeptides of corin can be utilized in methods to identify modulators of its activity, in animal models to mimic human disease, and to treat kidney, cardiovascular, and other conditions in which corin is involved.Type: ApplicationFiled: August 26, 2004Publication date: February 3, 2005Inventors: John Morser, Qingyu Wu, Wei Yan
-
Publication number: 20050003416Abstract: This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.Type: ApplicationFiled: June 9, 2004Publication date: January 6, 2005Applicant: Schering AktiengesellschaftInventor: Qingyu Wu
-
Patent number: 6806075Abstract: The present invention relates to a corin polypeptide which contains one or more frizzled corin and possesses various activities, including, e.g., serin protease activity and a pro-ANF converting activity, LDLR, SRCR repeats, serine protease catalytic domains such as human and mouse corin. The invention further relates to methods of using such nucleic acids and polypeptides in therapeutics, diagnostics, and research. For example, the nucleic acids and polypeptides of corin can be utilized in methods to identify modulators of its activity, in animal models to mimic human disease, and to treat kidney, cardiovascular, and other conditions in which corin is involved.Type: GrantFiled: June 25, 2002Date of Patent: October 19, 2004Assignee: Schering AGInventors: John Michael Morser, Qingyu Wu, Wei Yan
-
Publication number: 20040132156Abstract: The present invention provides modified hepsin molecules, or fragments or derivatives thereof, including those having a substitute activation sequence. The modified hepsin molecules are cleaved at the substitute activation sequence, thereby generating activated modified hepsin molecule, or fragments or derivatives thereof, that exhibit the functional activity of naturally-occurring, wild-type hepsin molecules.Type: ApplicationFiled: October 2, 2003Publication date: July 8, 2004Applicant: Schering AktiengesellschaftInventors: Gordon Parry, David Vogel, Marc Whitlow, Qingyu Wu
-
Publication number: 20030223976Abstract: This invention provides a novel expression control region isolated from mammalian corin genes. This control region preferentially activates transcription in cardiac cells. Methods and compositions are provided to employ this control region for identification of agents capable of modulating corin expression and for treatment of cardiac disease.Type: ApplicationFiled: May 28, 2003Publication date: December 4, 2003Applicant: Schering AktiengesellchaftInventors: Junliang Pan, Qingyu Wu
-
Patent number: 5981830Abstract: The present invention provides a transgenic mouse comprising a disrupted hepsin gene. In particular, the invention provides methods of making the transgenic mouse comprising the disrupted hepsin gene by utilizing a hepsin targeting vector for homologous recombination in mouse embryonic stem cells. Also, nucleotide and amino acid hepsin sequences are disclosed.Type: GrantFiled: December 30, 1997Date of Patent: November 9, 1999Assignees: Schering Aktiengesellschaft, Washington UniversityInventors: Qingyu Wu, Jasper E. Sadler